menu
    • menu
    [{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Cook MyoSite","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lipella Pharmaceuticals \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"LP-410","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Lipella Pharmaceuticals

    Menu

    Lipella Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Reports Early Tolerability Results in Ph 2 Trial of LP-310 for Oral Lichen Planus

                            Details : LP-310 is a oral rinse formulation of liposomal tacrolimus, it binds to FK506 binding protein inhibiting calcineurin phosphatase, currently being investigated for the treatment of oral Lichen Planus.

                            Brand Name : LP-310

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 24, 2024

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Doses First Two Patients in Phase 2a Oral Lichen Planus Trial

                            Details : LP-310 is a oral rinse formulation of liposomal tacrolimus, it binds to FK506 binding protein inhibiting calcineurin phosphatase, currently being investigated for the treatment of oral Lichen Planus.

                            Brand Name : LP-310

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Enrolls First Patients for LP-310 in Oral Lichen Planus Trial

                            Details : LP-310 (FKBP-12 binder) is a oral rinse formulation of LP-10 (liposomal-tacrolimus), being investigated for the treatment of Oral Lichen Planus.

                            Brand Name : LP-310

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Completes Site Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

                            Details : LP-310 (FKBP-12 binder) is a oral rinse formulation of LP-10 (liposomal-tacrolimus), being investigated for the treatment of Oral Lichen Planus.

                            Brand Name : LP-310

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2024

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Advances Lead Candidate to Phase 2b Following FDA Type-C Meeting

                            Details : LP-10 is an intravesical liposomal formulation of tacrolimus, intended for the treatment of patients suffering from moderate to severe hemorrhagic cystitis.

                            Brand Name : LP-10

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LP-410

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Announces FDA Clearance of IND for LP-410 in Oral Graft-Versus-Host Disease

                            Details : LP-410 is designed to target the underlying mechanisms of Oral Graft-Versus-Host Disease (GVHD), potentially providing a safe and effective treatment option for affected individuals.

                            Brand Name : LP-410

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            March 05, 2024

                            Lead Product(s) : LP-410

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

                            Details : LP-310 is a oral rinse formulation of LP-10, which is act as Increased local concentration in oral cavity while minimalizing systemic toxicity, which is investigated for the treatment of Graft-versus-Host Disease.

                            Brand Name : LP-310

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 10, 2023

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

                            Details : LP-310 is a oral rinse formulation of LP-10, which is act as Increased local concentration in oral cavity while minimalizing systemic toxicity, which is investigated for the treatment of oral Lichen Planus.

                            Brand Name : LP-310

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 20, 2023

                            Lead Product(s) : Liposomal Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Recipient : Cook MyoSite

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

                            Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

                            Brand Name : LP-10

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 17, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Recipient : Cook MyoSite

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

                            Details : LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. The product candidate is currently in Phase 2a clinical trial.

                            Brand Name : LP-10

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth